Logo image of TKNO

ALPHA TEKNOVA INC (TKNO) Stock Fundamental Analysis

NASDAQ:TKNO - Nasdaq - US02080L1026 - Common Stock - Currency: USD

5.91  +0.11 (+1.9%)

Fundamental Rating

3

Taking everything into account, TKNO scores 3 out of 10 in our fundamental rating. TKNO was compared to 55 industry peers in the Life Sciences Tools & Services industry. While TKNO seems to be doing ok healthwise, there are quite some concerns on its profitability. TKNO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TKNO has reported negative net income.
In the past year TKNO has reported a negative cash flow from operations.
TKNO had negative earnings in 4 of the past 5 years.
TKNO had negative operating cash flow in 4 of the past 5 years.
TKNO Yearly Net Income VS EBIT VS OCF VS FCFTKNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

The Return On Assets of TKNO (-22.52%) is worse than 61.82% of its industry peers.
TKNO has a Return On Equity (-32.46%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -22.52%
ROE -32.46%
ROIC N/A
ROA(3y)-27.43%
ROA(5y)-17.44%
ROE(3y)-40.28%
ROE(5y)-25.3%
ROIC(3y)N/A
ROIC(5y)N/A
TKNO Yearly ROA, ROE, ROICTKNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

Looking at the Gross Margin, with a value of 19.16%, TKNO is doing worse than 83.64% of the companies in the same industry.
In the last couple of years the Gross Margin of TKNO has declined.
TKNO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.25%
GM growth 5Y-14.67%
TKNO Yearly Profit, Operating, Gross MarginsTKNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

5

2. Health

2.1 Basic Checks

TKNO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TKNO has been increased compared to 1 year ago.
The number of shares outstanding for TKNO has been increased compared to 5 years ago.
The debt/assets ratio for TKNO is higher compared to a year ago.
TKNO Yearly Shares OutstandingTKNO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TKNO Yearly Total Debt VS Total AssetsTKNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 3.72 indicates that TKNO is not in any danger for bankruptcy at the moment.
The Altman-Z score of TKNO (3.72) is better than 74.55% of its industry peers.
TKNO has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.11, TKNO is doing good in the industry, outperforming 61.82% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z 3.72
ROIC/WACCN/A
WACC10.75%
TKNO Yearly LT Debt VS Equity VS FCFTKNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

TKNO has a Current Ratio of 3.82. This indicates that TKNO is financially healthy and has no problem in meeting its short term obligations.
TKNO's Current ratio of 3.82 is fine compared to the rest of the industry. TKNO outperforms 63.64% of its industry peers.
TKNO has a Quick Ratio of 3.21. This indicates that TKNO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of TKNO (3.21) is better than 61.82% of its industry peers.
Industry RankSector Rank
Current Ratio 3.82
Quick Ratio 3.21
TKNO Yearly Current Assets VS Current LiabilitesTKNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

TKNO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.39%, which is quite impressive.
Looking at the last year, TKNO shows a small growth in Revenue. The Revenue has grown by 2.89% in the last year.
TKNO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.68% yearly.
EPS 1Y (TTM)48.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y0.77%
Revenue growth 5Y12.68%
Sales Q2Q%5.44%

3.2 Future

TKNO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.37% yearly.
Based on estimates for the next years, TKNO will show a quite strong growth in Revenue. The Revenue will grow by 16.62% on average per year.
EPS Next Y30.85%
EPS Next 2Y17.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.12%
Revenue Next 2Y12.25%
Revenue Next 3YN/A
Revenue Next 5Y16.62%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TKNO Yearly Revenue VS EstimatesTKNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 20M 40M 60M 80M 100M
TKNO Yearly EPS VS EstimatesTKNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TKNO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TKNO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TKNO Price Earnings VS Forward Price EarningsTKNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TKNO Per share dataTKNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as TKNO's earnings are expected to grow with 17.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.37%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TKNO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALPHA TEKNOVA INC

NASDAQ:TKNO (5/29/2025, 8:17:18 PM)

5.91

+0.11 (+1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)N/A N/A
Inst Owners11.93%
Inst Owner Change-3.61%
Ins Owners9.33%
Ins Owner Change0%
Market Cap315.83M
Analysts80
Price Target11.22 (89.85%)
Short Float %27.79%
Short Ratio5.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.29%
Min EPS beat(2)-30.72%
Max EPS beat(2)10.13%
EPS beat(4)3
Avg EPS beat(4)5.03%
Min EPS beat(4)-30.72%
Max EPS beat(4)21.57%
EPS beat(8)6
Avg EPS beat(8)7.02%
EPS beat(12)8
Avg EPS beat(12)-8.37%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.17%
Min Revenue beat(2)2.17%
Max Revenue beat(2)4.18%
Revenue beat(4)3
Avg Revenue beat(4)3.4%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)7.66%
Revenue beat(8)5
Avg Revenue beat(8)3.98%
Revenue beat(12)9
Avg Revenue beat(12)5.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.03%
EPS NY rev (1m)0.83%
EPS NY rev (3m)-2.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.15%
Revenue NY rev (1m)-0.78%
Revenue NY rev (3m)-3.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.37
P/FCF N/A
P/OCF N/A
P/B 3.83
P/tB 4.56
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.71
BVpS1.54
TBVpS1.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.52%
ROE -32.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.16%
FCFM N/A
ROA(3y)-27.43%
ROA(5y)-17.44%
ROE(3y)-40.28%
ROE(5y)-25.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.25%
GM growth 5Y-14.67%
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.1%
Cap/Sales 2.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.82
Quick Ratio 3.21
Altman-Z 3.72
F-Score4
WACC10.75%
ROIC/WACCN/A
Cap/Depr(3y)348.43%
Cap/Depr(5y)400.74%
Cap/Sales(3y)30.86%
Cap/Sales(5y)32.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55%
EPS Next Y30.85%
EPS Next 2Y17.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2.89%
Revenue growth 3Y0.77%
Revenue growth 5Y12.68%
Sales Q2Q%5.44%
Revenue Next Year8.12%
Revenue Next 2Y12.25%
Revenue Next 3YN/A
Revenue Next 5Y16.62%
EBIT growth 1Y16.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.57%
EBIT Next 3YN/A
EBIT Next 5Y17.51%
FCF growth 1Y49.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.14%
OCF growth 3YN/A
OCF growth 5YN/A